Summary from ASCO 2020 virtual meeting

This article nicely summarises the most exciting research highlights from the ASCO 2020 Virtual Scientific Programme which demonstrate the evolution of treatments for advanced renal cell carcinoma (RCC), with a focus on combination treatments, salvage therapies and treatments for non-clear cell RCC. Read the review article in the Journal of Clinical Oncology here

read more

ASCO 2020: Lenvatinib plus pembrolizumab for disease progression after immunotherapy for metastatic kidney cancer

Results from a phase II trial of a combination of lenvatinib plus pembrolizumab for the treatment of metastatic renal cell carcinoma (RCC) which was not responding to treatment with immune checkpoint inhibitor therapy was presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program last weekend. One hundred and four (104) patients […]

read more

ASCO 2020: Subtypes of kidney cancer differ in sites of metastases

A paper presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program last weekend showed that histologic subtypes of metastatic renal cell carcinoma (RCC) differ in the location of their metastases. For example, lung, adrenal, brain, and pancreatic metastases occur more frequently with clear cell RCC than with papillary RCC or chromophobe […]

read more

ASCO 2020: Nivolumab plus ipilimumab combination for previously treated kidney cancer

Results from the phase II FRACTION-RCC clinical trial to assess the nivolumab plus ipilimumab combination in previously treated advanced renal cell carcinoma (RCC) patients were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program at the weekend. The study looked at 46 patients with previously treated RCC that was not responding to […]

read more

ASCO 2020: Bevacizumab and erlotinib for advanced hereditary leiomyomatosis RCC and papillary RCC

Results from a phase II study of bevacizumab and erlotinib in people with advanced hereditary leiomyomatosis and papillary renal cell cancer (HLRCC) or sporadic papillary RCC were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program at the weekend. This study included 83 patients with papillary RCC. Half of the patients […]

read more

ASCO 2020: Optimised treatment of advanced kidney cancer with nivolumab and ipilimumab

Two studies were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program to investigate whether initial treatment of metastatic renal cell carcinoma (RCC) patients with nivolumab followed by the addition of ipilimumab for patients with either stable or progressive disease would be as effective as upfront combination therapy and with less side […]

read more

ASCO 2020: Biomarkers for immunotherapy treatment for advanced kidney cancer

Biomarkers enable doctors predict which patients will respond to which drugs, and have an important role in many cancers. However, a good biomarker has not yet been found for renal cell carcinoma (RCC). The fundamental issue in the biology of metastatic RCC is that a suitable genetic mutation that ‘drives’ the development of RCC has […]

read more

ASCO 2020: HIF-2 alpha inhibitor induced positive response for VHL-associated kidney cancer

Results from a phase II international trial led by researchers at MD Anderson Cancer Center in America were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program. The trial showed treatment with a novel hypoxia inducible factor (HIF)-2 alpha inhibitor (MK-6482) was well tolerated and resulted in clinical responses in patients with von […]

read more

ASCO 2020: Factors influencing outcomes in kidney cancer treated with immunotherapy

A study presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program has identified several features of kidney cancer tumours that influence their response to immune checkpoint inhibitors, such as nivolumab and pembrolizumab. The research was conducted at the Dana-Farber Cancer Institute in America and is published in the journal, Nature Medicine. […]

read more

ASCO 2020: Pembrolizumab/axitinib combination for the treatment of advanced kidney cancer

Updated results from the KEYNOTE-426 study of pembrolizumab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma (RCC) were presented during the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program over the weekend. The combination of pembrolizumab with axitinib continues to show improved efficacy in the treatment of advanced RCC […]

read more
Showing 1 to 10 of 27 results
  TOP